HGHFX Mutual Fund

HGHFX Mutual Fund

NAV$50.69
See how much of HGHFX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$26M
Expense Ratio
0.92%
Dividend Yield (Current)
-
Holdings
83
Inception Date
Feb 28, 2017
Fund Family
Hartford Funds
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+15.13%
1 Year+25.63%
3 Year+14.89%
5 Year+4.66%
10 Year+8.47%

Asset Allocation

Stocks: 99.79%
Other: 0.21%
See how much of HGHFX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co11.62%
JNJJohnson & Johnson - Common6.71%
MRKMerck & Company Inc6.42%
ABBVAbbvie Inc.4.33%
UNHUnitedhealth Group Incorporated4.27%
Top 10 Concentration: 47.14%Report Date: Aug 31, 2026
Download all 83 holdings for HGHFX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Frequency
Annually
Latest Distribution
$4.37
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

HGHFX Mutual Fund Overview

HGHFX Mutual Fund (The Hartford Healthcare Fund Class F) is managed by Hartford Funds with $26.1M in net assets. HGHFX expense ratio is 0.92%, holding 83 positions across sectors including Health Care, Financials, Information Technology. Inception date: 2017-02-28.

HGHFX performance shows a YTD return of 15.13%. The 1-year return is 25.63% and the 5-year return is 4.66%.

HGHFX top holdings include Eli Lilly & Co (11.6%), Johnson & Johnson - Common (6.7%), Merck & Company Inc (6.4%), Abbvie Inc. (4.3%), Unitedhealth Group Incorporated (4.3%). Go to all HGHFX holdings, HGHFX sectors, or HGHFX dividends.

HGHFX can be compared against other funds. Use HGHFX overlap to find shared positions, or HGHFX vs another fund for a side-by-side view. HGHFX alternatives are available via the screener, along with tax-loss harvesting opportunities.